Clinical Trial

Protein-Distinct Macronutrient-Equivalent Diet 1

Study acronym: PRODMED1
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Plant-based diets are naturally low in Methionine (Met), and also low in precursor molecules (e.g L-carnitine, choline, betaine, etc.) producing microbiota-mediated proatherogenic TMAO. Among plant proteins, pulses are rich in micronutrients, and dietary fibers, making them ideal for microbiome-stimulating, nutrient-dense, healthful dietary patterns. However, daily pulse intake remains low at 8% in America despite recommendations by DGA, a resource to guide health promotion across communities. A significant body of preclinical data, waiting to be translated to humans, suggests that dietary Met restriction can trigger beneficial metabolic and anti-inflammatory adaptations leading to improved chronic health and longevity. The central hypothesis is that a pulse-protein-based healthy diet can be simultaneously equivalent to omnivorous diets in protein content and yet naturally lower in Met and TMAO to improve glycemic control, body composition, and immunometabolic flexibility to reduce the risk of chronic diseases and improve healthspan. The goal is to systematically elucidate for the first time the effects of a lacto-vegetarian feeding pattern with pulses as the primary protein source on a comprehensive panel of \~500 traditional and next-generation biomarkers of health, and assess the role of the gut microbiota in mediating such effects. We also aim to interrogate the potential concern about the lower bioavailability of non-heme iron from pulses.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-10-11; most recent amendment 2025-02-14.
Status change: Recruiting → Active, Not Recruiting 2023-09-11
Status change: Not Yet Recruiting → Recruiting 2023-04-11
Trial Details
NCT Number NCT05577858
Lead Sponsor South Dakota State University
Conditions Healthy Lifestyle
Enrollment 76 participants
Start Date 2022-11-15
Primary Completion 2023-12-20 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-17